Elena Gabriela Chiorean MD

Oncology•Seattle, WA

Gastrointestinal Cancer

Professor, Medicine, U of WA Sch of Med

Join to View Full Profile

825 Eastlake Ave EastLG-465Seattle, WA 98108
Phone+1 206-606-6324
Fax+1 206-606-1090

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 1999 - 2002
Corewell Health East Beaumont (Royal Oak)Residency, Internal Medicine, 1995 - 1998
Iuliu Hatieganu University of Medicine and PharmacyClass of 1993

Certifications & Licensure

WA State Medical License 2012 - 2025
IN State Medical License 2004 - 2013
MN State Medical License 1999 - 2004
MI State Medical License 1997 - 2001
American Board of Internal Medicine Medical Oncology

Clinical Trials

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer Start of enrollment: 2005 May 01
Terminated
Phase 2
Metabolomics-Based Detection of Colorectal Cancer Start of enrollment: 2007 Jul 01
Completed
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas Start of enrollment: 2007 Sep 01
Terminated
Phase 2
Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors Start of enrollment: 2008 Jan 23
Completed
Phase 1
Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps Start of enrollment: 2009 Jan 01
Completed
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18
Completed
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Start of enrollment: 2010 Oct 15
Completed
Phase 2
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer Start of enrollment: 2011 Jun 01
Withdrawn
Phase 2
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma Start of enrollment: 2013 Apr 01
Completed
Phase 1
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer Start of enrollment: 2013 Apr 01
Terminated
Phase 2
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer Start of enrollment: 2015 Nov 05
Completed
Phase 1
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer Start of enrollment: 2019 May 10
COMPLETED
PHASE3
Join now to see all

Publications & Presentations

PubMed

HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma.
Naomi Yamamoto, Stephanie Dobersch, Ian Loveless, Annie N Samraj, Gun Ho Jang
Clinical Cancer Research. 2025-02-17
Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.
Erkut H Borazanci, Nathan Bahary, Vincent Chung, Timothy K Huyck, Ebenezer A Kio
The Oncologist. 2024-11-04
16 citations
KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas.
Adam C Diehl, Lindsay M Hannan, David B Zhen, Andrew L Coveler, Gentry King
The Oncologist. 2022-12-09

Lectures

The Role of GLI-SOX2 Signaling Axis for Gemcitabine Resistance in Pancreatic Cancer
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

New Study in JNCCN Supports Chemotherapy Option That Reduces Side Effects for People with Gastrointestinal CancersSeptember 5th, 2024